Study describes the use of a non-cytotoxic dose of histone deacetylase (HDAC) inhibitors to induce pulmonary carcinoid somatostatin receptor subtype 2 (SSTR2) expression to diagnose pulmonary carcinoids.
UNT Health Science Center is one of the nation's premier graduate academic medical centers, with five schools that specialize in patient-centered education, research, and health care: Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, School of Public Health, School of Health Professions, and UNT System College of Pharmacy.
Study describes the use of a non-cytotoxic dose of histone deacetylase (HDAC) inhibitors to induce pulmonary carcinoid somatostatin receptor subtype 2 (SSTR2) expression to diagnose pulmonary carcinoids.
Physical Description
14 p.
Notes
Abstract: Pulmonary carcinoids are a type of neuroendocrine tumor (NET) accounting for 1–2% of lung cancer cases. Currently, Positron Emission Tomography (PET)/CT based on the radiolabeled sugar analogue [18F]-FDG is used to diagnose and stage pulmonary carcinoids, but is suboptimal due to low metabolic activity in these tumors. A new technique for pulmonary carcinoid imaging, using PET/CT with radiolabeled somatostatin analogs that specifically target somatostatin receptor subtype 2 (SSTR2), is becoming more standard, as many tumors overexpress SSTR2. However, pulmonary carcinoid patients with diminished SSTR2 expression are not eligible for this imaging or any type of SSTR2-specific treatment. We have found that histone deacetylase (HDAC) inhibitors can upregulate the expression of SSTR2 in pulmonary carcinoid cell lines. In this study, we used a non-cytotoxic dose of HDAC inhibitors to induce pulmonary carcinoid SSTR2 expression in which we confirmed in vitro and in vivo. A non-cytotoxic dose of the HDAC inhibitors: thailandepsin A (TDP-A), romidepsin (FK228), suberoylanilide hydroxamic acid (SAHA), AB3, and valproic acid (VPA) were administered to promote SSTR2 expression in pulmonary carcinoid cell lines and xenografts. This SSTR2 upregulation technique using HDAC inhibitors could enhance radiolabeled somatostatin analog-based imaging and the development of potential targeted treatments for pulmonary carcinoid patients with marginal or diminished SSTR2 expression.
This article is part of the following collection of related materials.
UNT Scholarly Works
Materials from the UNT community's research, creative, and scholarly activities and UNT's Open Access Repository. Access to some items in this collection may be restricted.
Guenter, Rachael E.; Aweda, Tolulope; Matos, Danilea M. Carmona; Whitt, Jason; Chang, Alexander W.; Cheng, Eric Y. et al.Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors,
article,
June 3, 2019;
[Basel, Switzerland].
(https://digital.library.unt.edu/ark:/67531/metadc1638205/:
accessed May 31, 2024),
University of North Texas Libraries, UNT Digital Library, https://digital.library.unt.edu;
crediting UNT Health Science Center.
